Vaccination with anti-idiotype antibody ganglidiomab mediates a GD 2-specific anti-neuroblastoma immune response

Cancer Immunology, Immunotherapy

Volumn 62, Issue 6, 2013, Pages 999-1010

  Lode, Holger N ^a   Schmidt, Manuela ^a   Seidel, Diana ^a   Huebener, Nicole ^a   Brackrock, Diana ^a   Bleeke, Matthias ^a   Reker, Daniel ^a   Brandt, Sven ^b   Mueller, Hans Peter ^b   Helm, Christiane ^b   Siebert, Nikolai ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Anti idiotype; Ganglioside GD2; Immunotherapy; Neuroblastoma; Pediatric oncology

Indexed keywords

ALUMINUM HYDROXIDE; ANTIIDIOTYPIC ANTIBODY; GANGLIDIOMAB; GANGLIOSIDE GD2; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DISSOCIATION CONSTANT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BINDING, COMPETITIVE; CANCER VACCINES; CELL LINE, TUMOR; GANGLIOSIDES; HUMANS; KINETICS; MICE; MOLECULAR SEQUENCE DATA; NEUROBLASTOMA; PROTEIN BINDING; SEQUENCE ALIGNMENT;

EID: 84878849601     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1413-y     Document Type: Article

References (24)

1. Yang RK, Sondel PM (2010) Anti-GD2 strategy in the treatment of neuroblastoma. Drugs Future 35:665
2. Modak S, Cheung NK (2007) Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 25:67-77
3. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334
4. Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J et al (2005) Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol 42:1311-1319
5. Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee MB (1998) Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J Immunother 21:75-83
6. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA (2002) Anti-idiotype antibody vaccine therapy for cancer. Expert Opin Biol Ther 2:869-881
7. Becker R, Eichler MK, Jennemann R, Bertalanffy H (2002) Phase I clinical trial on adjuvant active immunotherapy of human gliomas with GD2-conjugate. Br J Neurosurg 16:269-275
8. Chapman PB, Morrisey D, Panageas KS, Williams L, Lewis JJ, Israel RJ et al (2000) Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin Cancer Res 6:4658-4662
9. Fest S, Huebener N, Weixler S, Bleeke M, Zeng Y, Strandsby A et al (2006) Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res 66:10567-10575
10. Basak S, Birebent B, Purev E, Somasundaram R, Maruyama H, Zaloudik J et al (2003) Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother 52:145-154
11. Esser R, Muller T, Stefes D, Kloess S, Seidel D, Gillies SD et al (2012) NK cells engineered to express a GD(2)-specific antigen receptor display built-in ADCC-like activity against tumor cells of neuroectodermal origin. J Cell Mol Med 16:569-581
12. Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA (1997) Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 89:1586-1594
13. Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R et al (2000) Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J Immunol Methods 233:167-177
14. Larrick JW, Danielsson L, Brenner CA, Abrahamson M, Fry KE, Borrebaeck CA (1989) Rapid cloning of rearranged immunoglobulin genes from human hybridoma cells using mixed primers and the polymerase chain reaction. Biochem Biophys Res Commun 160:1250-1256
15. Coloma MJ, Hastings A, Wims LA, Morrison SL (1992) Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 152:89-104
16. Neri S, Mariani E, Meneghetti A, Cattini L, Facchini A (2001) Calcein-acetoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol 8:1131-1135
17. Huebener H, Fest S, Strandsby A, Michalsky E, Preissner R, Zeng Y et al (2008) A rationally designed tyrosine hydroxylase DNA vaccine induces specific anti-neuroblastoma immunity. Mol Cancer Ther 7:2241-2251
18. Zeytin HE, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, Chatterjee SK (2000) Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Ther 7:1426-1436
19. Hevey R, Ling CC (2012) Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies. Future Med Chem 4:545-584
20. Foon KA, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M et al (1998) Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 4:1117-1124
21. Sen G, Chakraborty M, Foon KA, Reisfeld RA, Bhattacharya-Chatterjee MB (1998) Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J Immunother 21:75-83
22. Batova A, Strother DR, Castleberry RP, Eskenazi EE, Yu A (2002) Immune responses to an anti-idiotype monoclonal antibody 1A7 as a tumor vaccine in children with high risk neuroblastoma. AACR Proc 43 (Abstract)
23. Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC et al (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 28:4969-4975
24. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:6050-6056